Protagonist Therapeutics, Inc.

19.97 USD
-0.39 (-1.92%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Protagonist Therapeutics, Inc. stock is up 28.92% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 7 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 PUT.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
11 Dec 17:05 19 Jan, 2024 20.00 PUT 200 9

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.